![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IR BioSciences Holdings Inc New (CE) | USOTC:IRBS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
ImmuneRegen's development candidate Homspera® appears to be the focus of their attention and it happens to be that the compound has several broad-reaching applications.
Study results have shown its ability to regenerate and strengthen the immune system and enhance wound healing, thereby providing possible treatments for acute radiation exposure, infectious diseases, vaccine adjuvancy, and chemical exposures.
The compound has been modulating the immune system. How it plays a role for various indications has increased the company's confidence in its candidacy for various large market opportunities as well as a rumored and yet to be publicly announced partnership with one integrated pharmaceutical industry player as they get further into clinical studies. That same company has a high level of interest (as do other entities) in purchasing the company's compound as a therapy for cancer -- melanoma specifically.
A complete report on the company with quotes from its CEO Michael Wilhelm is available now at BioMedReports.Com:
http://biomedreports.com/articles/most-popular/26267-immuneregen-otcbb-irbs-gaining-attention-for-its-stem-cell-active-compound-.html
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
Media Contact: Mary Davila Assistant Editor BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556
1 Year IR BioSciences (CE) Chart |
1 Month IR BioSciences (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions